What is a stock summary page? Click here for an overview.
Business Description
Siemens Healthineers AG
ISIN : DE000SHL1006
Share Class Description:
MEX:SHL N: Registered SharesCompare
Compare
Traded in other countries / regions
SHL.Germany0PMJ.UKSMMNY.USASHL.Austria1SHL.ItalySHL.BulgariaSHL.SwitzerlandSHL N.Mexico IPO Date
2021-04-19Description
Siemens Healthineers is engaged in therapeutic imaging, radiotherapy, laboratory, and point-of-care diagnostics. The imaging segment (55% of sales in fiscal 2024) includes magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound. The Varian segment (17% of sales) offers radiotherapy and other oncology solutions. The portfolio of the diagnostics segment (20%) includes in vitro diagnostics products offered to providers and point-of-care diagnostics. The advanced therapies segment (9%) products are designed to support image-guided minimally invasive treatments in cardiology, interventional radiology, and surgery. Americas represents 42% of total sales, Europe, Middle East, and Africa 33%, and Asia-Pacific including China the remainder.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.68 | |||||
| Equity-to-Asset | 0.41 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | 0.19 | |||||
| Interest Coverage | 6.1 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 1.89 | |||||
| Beneish M-Score | -2.59 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.9 | |||||
| 3-Year EBITDA Growth Rate | 5.6 | |||||
| 3-Year EPS without NRI Growth Rate | 3.3 | |||||
| 3-Year FCF Growth Rate | -2.5 | |||||
| 3-Year Book Growth Rate | 3.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 21.48 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 6.34 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 4.32 | |||||
| 9-Day RSI | 31.45 | |||||
| 14-Day RSI | 54.53 | |||||
| 6-1 Month Momentum % | 11.87 | |||||
| 12-1 Month Momentum % | 11.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.28 | |||||
| Quick Ratio | 0.89 | |||||
| Cash Ratio | 0.26 | |||||
| Days Inventory | 117.98 | |||||
| Days Sales Outstanding | 69.36 | |||||
| Days Payable | 54.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Payout Ratio | 0.52 | |||||
| 3-Year Dividend Growth Rate | 5.9 | |||||
| 3-Year Average Share Buyback Ratio | 0.1 | |||||
| Shareholder Yield % | 1.9 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 38.19 | |||||
| Operating Margin % | 12.84 | |||||
| Net Margin % | 8.76 | |||||
| FCF Margin % | 12.35 | |||||
| ROE % | 10.71 | |||||
| ROA % | 4.26 | |||||
| ROIC % | 5.75 | |||||
| 3-Year ROIIC % | 29.82 | |||||
| ROC (Joel Greenblatt) % | 69.75 | |||||
| ROCE % | 8.77 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 25.23 | |||||
| Forward PE Ratio | 20.7 | |||||
| PE Ratio without NRI | 25.23 | |||||
| Shiller PE Ratio | 26.55 | |||||
| Price-to-Owner-Earnings | 16.32 | |||||
| PEG Ratio | 4.51 | |||||
| PS Ratio | 2.21 | |||||
| PB Ratio | 2.53 | |||||
| Price-to-Free-Cash-Flow | 18.54 | |||||
| Price-to-Operating-Cash-Flow | 14.58 | |||||
| EV-to-EBIT | 15.87 | |||||
| EV-to-Forward-EBIT | 14.54 | |||||
| EV-to-EBITDA | 11.31 | |||||
| EV-to-Forward-EBITDA | 10.54 | |||||
| EV-to-Revenue | 2.15 | |||||
| EV-to-Forward-Revenue | 2.01 | |||||
| EV-to-FCF | 17.71 | |||||
| Price-to-GF-Value | 0.81 | |||||
| Price-to-Projected-FCF | 1.43 | |||||
| Price-to-Peter-Lynch-Fair-Value | 4.59 | |||||
| Earnings Yield (Greenblatt) % | 6.29 | |||||
| FCF Yield % | 5.31 | |||||
| Forward Rate of Return (Yacktman) % | 9.17 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Siemens Healthineers AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 459,237.244 | ||
| EPS (TTM) (MXN) | 36.025 | ||
| Beta | 0.21 | ||
| 3-Year Sharpe Ratio | -0.94 | ||
| 3-Year Sortino Ratio | -1.17 | ||
| Volatility % | 14.44 | ||
| 14-Day RSI | 54.53 | ||
| 14-Day ATR (MXN) | 0.010102 | ||
| 20-Day SMA (MXN) | 1083.01 | ||
| 12-1 Month Momentum % | 11.87 | ||
| 52-Week Range (MXN) | 968.11 - 1105.44 | ||
| Shares Outstanding (Mil) | 1,119.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Siemens Healthineers AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Siemens Healthineers AG Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
Siemens Healthineers AG Frequently Asked Questions
What is Siemens Healthineers AG(MEX:SHL N)'s stock price today?
The current price of MEX:SHL N is MXN1083.01. The 52 week high of MEX:SHL N is MXN1105.44 and 52 week low is MXN968.11.
When is next earnings date of Siemens Healthineers AG(MEX:SHL N)?
The next earnings date of Siemens Healthineers AG(MEX:SHL N) is 2025-05-07.
Does Siemens Healthineers AG(MEX:SHL N) pay dividends? If so, how much?
Siemens Healthineers AG(MEX:SHL N) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers